Now showing items 30-49 of 833

    • Alterations in the phosphoproteomic profile of cells expressing a non-functional form of the SHP2 phosphatase. 

      Corallino, S; Iwai, LK; Payne, LS; Huang, PH; Sacco, F; Cesareni, G; Castagnoli, L (2016-09)
      The phosphatase SHP-2 plays an essential role in growth factor signaling and mutations in its locus is the cause of congenital and acquired pathologies. Mutations of SHP-2 are known to affect the activation of the RAS ...
    • Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. 

      Sud, A; Chattopadhyay, S; Thomsen, H; Sundquist, K; Sundquist, J; Houlston, RS; Hemminki, K (2019-09)
      Estimating familial cancer risks is clinically important in being able to discriminate between individuals in the population at differing risk for malignancy. To gain insight into the familial risk for the different ...
    • Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer. 

      Nawaz, S; Trahearn, NA; Heindl, A; Banerjee, S; Maley, CC; Sottoriva, A; Yuan, Y (2019-10-21)
      BACKGROUND:Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer, at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratification. ...
    • Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. 

      Leung, SCY; Nielsen, TO; Zabaglo, LA; Arun, I; Badve, SS; Bane, AL; Bartlett, JMS; Borgquist, S; Chang, MC; Dodson, A; Ehinger, A; Fineberg, S; Focke, CM; Gao, D; Gown, AM; Gutierrez, C; Hugh, JC; Kos, Z; Laenkholm, A-V; Mastropasqua, MG; Moriya, T; Nofech-Mozes, S; Osborne, CK; Penault-Llorca, FM; Piper, T; Sakatani, T; Salgado, R; Starczynski, J; Sugie, T; van der Vegt, B; Viale, G; Hayes, DF; McShane, LM; Dowsett, M; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG) (2019-08)
      AIMS:The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The ...
    • Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. 

      Ragulan, C; Eason, K; Fontana, E; Nyamundanda, G; Tarazona, N; Patil, Y; Poudel, P; Lawlor, RT; Del Rio, M; Koo, S-L; Tan, W-S; Sclafani, F; Begum, R; Teixeira Mendes, LS; Martineau, P; Scarpa, A; Cervantes, A; Tan, IB; Cunningham, D; Sadanandam, A (2019-05-21)
      Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later consolidated into four consensus molecular subtypes (CMS). Here ...
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses 

      Dowsett, M (2003-11)
      BACKGROUND: The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage ...
    • Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. 

      Crespo, M; van Dalum, G; Ferraldeschi, R; Zafeiriou, Z; Sideris, S; Lorente, D; Bianchini, D; Rodrigues, DN; Riisnaes, R; Miranda, S; Figueiredo, I; Flohr, P; Nowakowska, K; de Bono, JS; Terstappen, LWMM; Attard, G (2015-03-31)
      BACKGROUND:Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells (CTCs)-based ...
    • Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. 

      Conteduca, V; Wetterskog, D; Sharabiani, MTA; Grande, E; Fernandez-Perez, MP; Jayaram, A; Salvi, S; Castellano, D; Romanel, A; Romanel, A; Lolli, C; Casadio, V; Gurioli, G; Amadori, D; Font, A; Vazquez-Estevez, S; González Del Alba, A; Mellado, B; Fernandez-Calvo, O; Méndez-Vidal, MJ; Climent, MA; Duran, I; Gallardo, E; Rodriguez, A; Santander, C; Sáez, MI; Puente, J; Gasi Tandefelt, D; Wingate, A; Dearnaley, D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group; Demichelis, F; De Giorgi, U; Gonzalez-Billalabeitia, E; Attard, G (2017-07)
      Background:There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma ...
    • Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. 

      Winfield, JM; Poillucci, G; Blackledge, MD; Collins, DJ; Shah, V; Tunariu, N; Kaiser, MF; Messiou, C (2018-04)
      OBJECTIVES:The aim of this study was to identify apparent diffusion coefficient (ADC) values for typical haemangiomas in the spine and to compare them with active malignant focal deposits. METHODS:This was a retrospective ...
    • Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. 

      Amirian, ES; Ostrom, QT; Armstrong, GN; Lai, RK; Gu, X; Jacobs, DI; Jalali, A; Claus, EB; Barnholtz-Sloan, JS; Il'yasova, D; Schildkraut, JM; Ali-Osman, F; Sadetzki, S; Jenkins, RB; Lachance, DH; Olson, SH; Bernstein, JL; Merrell, RT; Wrensch, MR; Johansen, C; Houlston, RS; Scheurer, ME; Shete, S; Amos, CI; Melin, B; Bondy, ML (2019-03)
      BACKGROUND:There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the ...
    • Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. 

      Went, M; Sud, A; Law, PJ; Johnson, DC; Weinhold, N; Försti, A; van Duin, M; Mitchell, JS; Chen, B; Kuiper, R; Stephens, OW; Bertsch, U; Campo, C; Einsele, H; Gregory, WM; Henrion, M; Hillengass, J; Hoffmann, P; Jackson, GH; Lenive, O; Nickel, J; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Walker, BA; Broyl, A; Davies, FE; Langer, C; Hansson, M; Kaiser, M; Sonneveld, P; Goldschmidt, H; Hemminki, K; Nilsson, B; Morgan, GJ; Houlston, RS (2017-06-16)
    • Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. 

      Fassan, M; Vianello, L; Sacchi, D; Fanelli, GN; Munari, G; Scarpa, M; Cappellesso, R; Loupakis, F; Lanza, C; Salmaso, R; Mescoli, C; Valeri, N; Agostini, M; D'Angelo, E; Lonardi, S; Pucciarelli, S; Veronese, N; Luchini, C; Rugge, M (2018-01)
      Background:No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node metastasis (LN) in colorectal cancer (CRC). Methods:A series of 22 ENE-positive CRCs was considered and three ...
    • Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. 

      Zhang, YD; Hurson, AN; Zhang, H; Choudhury, PP; Easton, DF; Milne, RL; Simard, J; Hall, P; Michailidou, K; Dennis, J; Schmidt, MK; Chang-Claude, J; Gharahkhani, P; Whiteman, D; Campbell, PT; Hoffmeister, M; Jenkins, M; Peters, U; Hsu, L; Gruber, SB; Casey, G; Schmit, SL; O'Mara, TA; Spurdle, AB; Thompson, DJ; Tomlinson, I; De Vivo, I; Landi, MT; Law, MH; Iles, MM; Demenais, F; Kumar, R; MacGregor, S; Bishop, DT; Ward, SV; Bondy, ML; Houlston, R; Wiencke, JK; Melin, B; Barnholtz-Sloan, J; Kinnersley, B; Wrensch, MR; Amos, CI; Hung, RJ; Brennan, P; McKay, J; Caporaso, NE; Berndt, SI; Birmann, BM; Camp, NJ; Kraft, P; Rothman, N; Slager, SL; Berchuck, A; Pharoah, PDP; Sellers, TA; Gayther, SA; Pearce, CL; Goode, EL; Schildkraut, JM; Moysich, KB; Amundadottir, LT; Jacobs, EJ; Klein, AP; Petersen, GM; Risch, HA; Stolzenberg-Solomon, RZ; Wolpin, BM; Li, D; Eeles, RA; Haiman, CA; Kote-Jarai, Z; Schumacher, FR; Al Olama, AA; Purdue, MP; Scelo, G; Dalgaard, MD; Greene, MH; Grotmol, T; Kanetsky, PA; McGlynn, KA; Nathanson, KL; Turnbull, C; Wiklund, F; Breast Cancer Association Consortium (BCAC); Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON); Colon Cancer Family Registry (CCFR); Transdisciplinary Studies of Genetic Variation in Colorectal Cancer (CORECT); Endometrial Cancer Association Consortium (ECAC); Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO); Melanoma Genetics Consortium (GenoMEL); Glioma International Case-Control Study (GICC); International Lung Cancer Consortium (ILCCO); Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium; International Consortium of Investigators Working on Non-Hodgkin’s Lymphoma Epidemiologic Studies (InterLymph); Ovarian Cancer Association Consortium (OCAC); Oral Cancer GWAS; Pancreatic Cancer Case-Control Consortium (PanC4); Pancreatic Cancer Cohort Consortium (PanScan); Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL); Renal Cancer GWAS; Testicular Cancer Consortium (TECAC); Chanock, SJ; Chatterjee, N; Garcia-Closas, M (2020-07-03)
      Genome-wide association studies (GWAS) have led to the identification of hundreds of susceptibility loci across cancers, but the impact of further studies remains uncertain. Here we analyse summary-level data from GWAS of ...
    • Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. 

      Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; O'Neill, S; Hills, M; Smith, I; Dowsett, M (2012-05)
      BACKGROUND:The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ...
    • Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. 

      Woolf, DK; Li, SP; Detre, S; Liu, A; Gogbashian, A; Simcock, IC; Stirling, J; Kosmin, M; Cook, GJ; Siddique, M; Dowsett, M; Makris, A; Goh, V (2019-01)
      Background:Tumour heterogeneity is considered an important mechanism of treatment failure. Imaging-based assessment of tumour heterogeneity is showing promise but the relationship between these mathematically derived ...
    • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

      Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
      Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
    • Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. 

      Telomeres Mendelian Randomization Collaboration; Haycock, PC; Burgess, S; Nounu, A; Zheng, J; Okoli, GN; Bowden, J; Wade, KH; Timpson, NJ; Evans, DM; Willeit, P; Aviv, A; Gaunt, TR; Hemani, G; Mangino, M; Ellis, HP; Kurian, KM; Pooley, KA; Eeles, RA; Lee, JE; Fang, S; Chen, WV; Law, MH; Bowdler, LM; Iles, MM; Yang, Q; Worrall, BB; Markus, HS; Hung, RJ; Amos, CI; Spurdle, AB; Thompson, DJ; O'Mara, TA; Wolpin, B; Amundadottir, L; Stolzenberg-Solomon, R; Trichopoulou, A; Onland-Moret, NC; Lund, E; Duell, EJ; Canzian, F; Severi, G; Overvad, K; Gunter, MJ; Tumino, R; Svenson, U; van Rij, A; Baas, AF; Bown, MJ; Samani, NJ; van t'Hof, FNG; Tromp, G; Jones, GT; Kuivaniemi, H; Elmore, JR; Johansson, M; Mckay, J; Scelo, G; Carreras-Torres, R; Gaborieau, V; Brennan, P; Bracci, PM; Neale, RE; Olson, SH; Gallinger, S; Li, D; Petersen, GM; Risch, HA; Klein, AP; Han, J; Abnet, CC; Freedman, ND; Taylor, PR; Maris, JM; Aben, KK; Kiemeney, LA; Vermeulen, SH; Wiencke, JK; Walsh, KM; Wrensch, M; Rice, T; Turnbull, C; Litchfield, K; Paternoster, L; Standl, M; Abecasis, GR; SanGiovanni, JP; Li, Y; Mijatovic, V; Sapkota, Y; Low, S-K; Zondervan, KT; Montgomery, GW; Nyholt, DR; van Heel, DA; Hunt, K; Arking, DE; Ashar, FN; Sotoodehnia, N; Woo, D; Rosand, J; Comeau, ME; Brown, WM; Silverman, EK; Hokanson, JE; Cho, MH; Hui, J; Ferreira, MA; Thompson, PJ; Morrison, AC; Felix, JF; Smith, NL; Christiano, AM; Petukhova, L; Betz, RC; Fan, X; Zhang, X; Zhu, C; Langefeld, CD; Thompson, SD; Wang, F; Lin, X; Schwartz, DA; Fingerlin, T; Rotter, JI; Cotch, MF; Jensen, RA; Munz, M; Dommisch, H; Schaefer, AS; Han, F; Ollila, HM; Hillary, RP; Albagha, O; Ralston, SH; Zeng, C; Zheng, W; Shu, X-O; Reis, A; Uebe, S; Hüffmeier, U; Kawamura, Y; Otowa, T; Sasaki, T; Hibberd, ML; Davila, S; Xie, G; Siminovitch, K; Bei, J-X; Zeng, Y-X; Försti, A; Chen, B; Landi, S; Franke, A; Fischer, A; Ellinghaus, D; Flores, C; Noth, I; Ma, S-F; Foo, JN; Liu, J; Kim, J-W; Cox, DG; Delattre, O; Mirabeau, O; Skibola, CF; Tang, CS; Garcia-Barcelo, M; Chang, K-P; Su, W-H; Chang, Y-S; Martin, NG; Gordon, S; Wade, TD; Lee, C; Kubo, M; Cha, P-C; Nakamura, Y; Levy, D; Kimura, M; Hwang, S-J; Hunt, S; Spector, T; Soranzo, N; Manichaikul, AW; Barr, RG; Kahali, B; Speliotes, E; Yerges-Armstrong, LM; Cheng, C-Y; Jonas, JB; Wong, TY; Fogh, I; Lin, K; Powell, JF; Rice, K; Relton, CL; Martin, RM; Davey Smith, G (2017-05)
      Importance:The causal direction and magnitude of the association between telomere length and incidence of cancer and non-neoplastic diseases is uncertain owing to the susceptibility of observational studies to confounding ...
    • Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. 

      Filipits, M; Dafni, U; Gnant, M; Polydoropoulou, V; Hills, M; Kiermaier, A; de Azambuja, E; Larsimont, D; Rojo, F; Viale, G; Toi, M; Harbeck, N; Prichard, KI; Gelber, RD; Dinh, P; Zardavas, D; Leyland-Jones, B; Piccart-Gebhart, MJ; Dowsett, M; TransHERA investigators (2018-07)
      Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer.Experimental Design: Protein expression ...
    • Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. 

      Büchel, G; Carstensen, A; Mak, K-Y; Roeschert, I; Leen, E; Sumara, O; Hofstetter, J; Herold, S; Kalb, J; Baluapuri, A; Poon, E; Kwok, C; Chesler, L; Maric, HM; Rickman, DS; Wolf, E; Bayliss, R; Walz, S; Eilers, M (2017-12)
      MYC proteins bind globally to active promoters and promote transcriptional elongation by RNA polymerase II (Pol II). To identify effector proteins that mediate this function, we performed mass spectrometry on N-MYC complexes ...
    • Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

      Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)
      BACKGROUND:Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM protein ...